AstraZeneca licenses Immunocore's T-Cell platform for potential $300m
AstraZeneca has become the third Big Biopharma to strike a deal with Immunocore to license its Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Archives for January 8, 2014
HyClone units to keep Utah and Colorado HQs says GE Healthcare
GE Healthcare has confirmed it will continue to run the HyClone units it is buying from Thermo Fisher Scientific from their existing US bases.
TxCell: personalised technique avoids cell therapy snags
Autoimmune biotechnology firm TxCell claims its manufacturing technique avoids the pitfalls of standard cell therapies like Provenge.